Find policies, billing codes, payers, states, and providers
HCPCS J1557: Immune Globulin (Gammaplex) IV, 500 mg
HCPCS Level II code J1557 designates a 500 mg unit of intravenous immune globulin Gammaplex in a liquid form. This code is significant nationally for reporting the medication component of immune globulin therapy across outpatient infusion settings. Accurate use of J1557 affects medication billing, inventory tracking, and payer reimbursement for high-cost biologic therapies administered intravenously.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how J1557 is applied across common infusion sites, and what stakeholders typically monitor when evaluating claims with this code.
Readers will learn: standardized code definition and clinical context for J1557; expected sites of service and service type; common billing considerations; and the types of benchmarks and policy updates that influence coverage and payment for intravenous immune globulin products. Data not available in the input will be noted where applicable.
Customize your policy alerts
Sign up for hcpcs J1557 policy alerts
Get alerted when payer policies referencing J1557 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J1557 describes an intravenous administration of immune globulin product Gammaplex, provided as a non-lyophilized (liquid) preparation, in a 500 mg unit. This code is used to report the medication itself rather than the infusion procedure.
Service Type: Intravenous immune globulin infusion (medication administration)
Typical Site of Service: Hospital outpatient infusion centers, physician office infusion suites, and ambulatory infusion clinics
Data not available in the input.